Briefs: Relonchem, Patel Chem Specialities and J & H Pharma Consultants
Relonchem receives marketing authorization for Moxonidine tablets
Relonchem receives marketing authorization for Moxonidine tablets
Hengrui is eligible to receive regulatory and commercial milestone payments of up to US$1.093 billion
Sessions will cover process mapping, cost optimisation, data-driven decision-making, cybersecurity, and sustainable manufacturing practices
Agency initiates safety label change and notifies physicians of possible link
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.
Subscribe To Our Newsletter & Stay Updated